NL-OMON41680
Recruiting
Phase 3
A randomized controlled trial into the efficacy of neurofeedback for treatment of major depressive disorder - Neurofeedback for depression
Medisch Universitair Ziekenhuis Maastricht0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- depression
- Sponsor
- Medisch Universitair Ziekenhuis Maastricht
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary axis\-1 disorder of Major Depressive Disorder fulfilling DSM\-IV\-TR criteria.
- •Written informed consent.
Exclusion Criteria
- •History of brain trauma (commotio or contusio cerebra) or CVA
- •Current use of antipsychotics, moodstabilizers or benzodiazepines. Current use of antidepressants is permitted if this medication is not changed within a period of 6 weeks prior to participation in the study. Additionally, no changes in antidepressant medication are allowed during active participation in the study.
- •Chronic depression (\> two years duration).
- •Dysthymia as a primary axis\-1 diagnosis
- •Bipolar disorder or schizophrenia as a primary axis\-1 diagnosis
- •Severe suicidality (HDRS item \# 3 with a score \>2\) or severe depression symptomatology (HDRS score \> 25\).
- •Pregnancy.
- •Age \< 18 years.
- •Daily alcoholintake of \>7 units.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)ITMCTR2000003033Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,
Completed
Not Applicable
Study on the effectiveness paracetamol two hours before Electro Convulsive Therapy (ECT) to reduce the incidence and severity of post ECT headache.Post ECT headacheSLCTR/2015/027Professorial Psychiatry Unit,
Completed
Phase 3
The randomized controlled trial of the efficacy of goshajinkigan, mecobalamin and lafutidine in breast cancer patients with chemotherapy-induced peripheral neuropathy.chemotherapy-induced peripheral neuropathyJPRN-UMIN000010969Department of breast and endocrine surgery, Meiwa Hospital50
Completed
Phase 3
The randomized controlled trial of the efficacy of goshajinkigan and lafutidine after mecobalamin administered in breast cancer patients with chemotherapy-induced peripheral neuropathy.chemotherapy-induced peripheral neuropathyJPRN-UMIN000010988Department of breast and endocrine surgery, Meiwa Hospital35
Completed
Phase 3
The randomized controlled trial of the efficacy of mecobalamin and lafutidine after goshajinkigan administered in breast cancer patients with chemotherapy-induced peripheral neuropathy.chemotherapy-induced peripheral neuropathyJPRN-UMIN000011007Department of breast and endocrine surgery, Meiwa Hospital35